Article date: April 2019
By: Kristel Paque, Robrecht De Schreye, Monique Elseviers, Robert Vander Stichele, Koen Pardon, Tinne Dilles, Thierry Christiaens, Luc Deliens, Joachim Cohen in Volume 85, Issue 4, pages 827-837
Aims
The aim of this study was to examine the use of potentially inappropriate medication (PIM) in relation to time before death, to explore whether PIMs are discontinued at the end of life, and the factors associated with this discontinuation.
Methods
We conducted a retrospective register‐based mortality cohort study of all deceased in 2012 in Belgium, aged at least 75 years at time of death (n = 74 368), using linked administrative databases. We used STOPPFrail to identify PIMs received during the period from 12 to 6 months before death (P1) and the last 4 months (P2) of life.
Results
Median age was 86 (IQR 81–90) at time of death, 57% were female, 38% were living in a nursing home, and 16% were admitted to hospital between 2 years and 4 months before death. Overall, PIM use was high, and increased towards death for all PIMs. At least one PIM was discontinued during P2 for one in five (20%) of the population, and 49% had no discontinuation. Being hospitalized in the period before the last 4 months of life, living in a nursing home, female gender and a higher number of medications used during P1 were associated with discontinuation of PIMs (respective aOR [95% CI]: 2.89 [2.73–3.06], 1.29 [1.23–1.36], 1.26 [1.20–1.32], 1.17 [1.16–1.17]).
Conclusion
Initial PIM use was high and increased towards death. Discontinuation was observed in only one in five PIM users. More guidance for discontinuation of PIMs is needed: practical, evidence‐based deprescribing guidelines and implementation plans, training for prescribers and a better consensus on what inappropriate medication is.
DOI: 10.1111/bcp.13874
View this article